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ABSTRACT 
 
Adiponectin, also called Acrp30, is a 30-kDa protein that circulates in the blood at high levels (2-10 µg/ml in 
human) and constitutes 0.01% of the total plasma protein.  In contrast to other adipokines such as leptin, 
adiponectin is believed to be an anti-inflammatory and insulin-sensitizing hormone whose levels are reduced in 
obesity. Adiponectin can exist in the blood as a trimer, with the potential to associate into hexamers and 
ﬁnally into multimers of high molecular weight (HMW) species. Adiponectin primarily mediates its insulin-sensitizing 
effects through various signaling proteins including the activation of adenosine monophosphate (AMP)-activated 
protein kinase (AMPK). Recent reports suggest the anti-inﬂammatory and cytoprotective effects of adiponectin are 
mediated by direct activation of PI3K-Akt pathway. Interestingly adiponectin is also reported to decrease body 
weight by centrally mediated stimulation of energy expenditure. 
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Introduction 
Adiponectin, also called Acrp30, is a 30-kDa 
protein that circulates in the blood at high levels (2-10 
µg/ml in human) and constitutes 0.01% of the total 
plasma protein.  In contrast to other adipokines such 
as leptin, adiponectin is believed to be an anti-
inflammatory and insulin-sensitizing hormone whose 
levels are reduced in obesity.1,2 Adiponectin can exist 
in the blood as a trimer, with the potential to associate 
into hexamers and ﬁnally into multimers of high 
molecular weight (HMW) species.3 Studies suggest that 
HMW adiponectin is the most metabolically active 
multimer. For example, the proportion of HMW 
adiponectin, rather than the total level, is associated 
with the beneficial effects of thiazolidinediones.2,3 
Furthermore, HMW adiponectin appears to modulate 
the antiatherogenic properties of adiponectin.2,3 
Interestingly, although secreted primarily by 
adipocytes, levels of this hormone are paradoxically 
reduced in obesity. Similarly, decreased adiponectin 
levels were seen in parallel with the progression of 
insulin resistance and T2D in nonhuman primates4, 
suggesting that maintaining high circulating 
adiponectin levels  may be a potential approach to 
preventing the development of these disorders. 
 
Mechanisms of adiponectin 
Adiponectin primarily mediates its insulin-
sensitizing effects through various signaling proteins 
including the activation of adenosine monophosphate 
(AMP)-activated protein kinase (AMPK).5 Recent 
reports suggest the anti-inﬂammatory and 
cytoprotective effects of adiponectin are mediated by 
direct activation of PI3K-Akt pathway. Interestingly 
adiponectin is also reported to decrease body weight 
by centrally mediated stimulation of energy 
expenditure.6 
 
Multimeric forms of adiponectin 
There are very little data assessing the 
metabolic significance of adiponectin multimeric 
forms. There was one recent article showing that the 
ratio of HMW to total adiponectin, not the total 
adiponectin level per se, was responsible for favorable 
metabolic effects.7 The authors found that the ratio of 
HMW to total adiponectin, and not total adiponectin, 
was correlated with insulin sensitivity in humans and 
rodents, and it was increased by thiazolidinedione 
drugs in proportion to increments in hepatic insulin 
sensitivity manifested by a decrease in fasting hepatic 
glucose output.7 In addition, administration of HMW 
but not LMW adiponectin lowered glucose in mice. In 
contrast, other studies have shown that LMW 
(hexamer) and HMW adiponectin are equally effective 
in activating nuclear factor-κB and that both the 
adiponectin monomer and trimer are capable of 
stimulating AMPK, whereas LMW and HMW 
adiponectin produce no effect. Thus, the manner and 
extent to which adiponectin multimeric forms may 
exert differential biological activity remains unclear. 
Nevertheless, these data have important and far-
ranging implications regarding previous data because 
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epidemiological studies have assessed total 
immunoreactive adiponectin, not multimeric forms. 
When glucose disposal rate was analyzed as a 
continuous variable, HMW and LMW adiponectin and 
the ratio of HMW to total adiponectin were positively 
correlated with glucose disposal rate. These 
associations persist even after controlling for effects of 
body adiposity and fat distribution, indicating that the 
relationships between total, HMW, and LMW 
adiponectin are independent of total body fat or fat 
distribution. These findings are in agreement with 
functional studies indicating that adiponectin 
multimers activate the AMPK pathway, which in turn 
induces fatty acid oxidation, glucose uptake, and 
lactate production in myocytes.8 
Higher levels of total adiponectin and HMW 
adiponectin were correlated with higher levels of the 
more cardioprotective large HDL particles as well as 
with higher HDL particle size, together with decreased 
concentrations of both large VLDL particles and small 
LDL particles. Typically, the associations between 
HMW adiponectin and the various lipoprotein 
subclass parameters were higher than those observed 
for total adiponectin; these data reflect the colinearity 
between total and HMW adiponectin and suggest that 
the lipoprotein effects of total adiponectin are mainly 
driven by the more biologically active HMW 
multimer.9 
 
Concluding remarks  
It is HMW quantity, not total adiponectin or 
the ratio of multimeric forms, which is primarily 
responsible for these relationships. Still, the role of 
LMW adiponectin deserves further exploration 
because it was also correlated with insulin sensitivity 
and basal lipid oxidation. HMW adiponectin is an 
important biomarker for the metabolic syndrome and 
could play a pathogenic role in the development of the 
insulin resistance. 
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